CDKL4 Antibody

Definition and Biological Role of CDK4 Antibodies

CDK4 antibodies are immunological tools designed to detect and study cyclin-dependent kinase 4, a serine/threonine kinase critical for cell cycle progression from G1 to S phase. These antibodies recognize specific epitopes, including phosphorylated residues (e.g., T172), and are used to investigate CDK4's role in cancer proliferation and therapeutic targeting .

Development of Phosphorylation-Specific CDK4 Antibodies

Novel monoclonal antibodies targeting T172-phosphorylated CDK4 were developed using a phosphopeptide corresponding to CDK4's activation segment. Key advancements include:

These antibodies enable precise detection of CDK4 activation status, which correlates with tumor responsiveness to palbociclib and other CDK4/6 inhibitors .

Diagnostic and Prognostic Applications in Cancer

CDK4 antibodies are widely used in immunohistochemistry (IHC) for tumor typing:

• Liposarcomas: Overexpression observed in 92% of atypical lipomatous tumors (ALT-WDLPS) and dedifferentiated liposarcomas (DDLPS) .

• Breast and Lung Cancers: High CDK4 levels correlate with tumor progression and resistance to standard therapies .

• Colon Carcinoma: Nuclear localization of CDK4 aids in differentiating malignant from benign lesions .

Role in Immunotherapy and Immune Modulation

CDK4/6 inhibitors (e.g., palbociclib) enhance antitumor immunity through T-cell activation:

In murine models, combining CDK4/6 inhibitors with PD-1 blockade eradicated tumors in 40% of cases, compared to 10% with monotherapy .

Research Limitations and Future Directions

• Technical Challenges: Traditional methods like 2D-IEF for detecting CDK4 phosphorylation are labor-intensive .

• Therapeutic Trade-offs: Prolonged CDK4/6 inhibition may suppress T-cell proliferation despite early immunostimulatory effects .

• Biomarker Validation: Clinical trials are needed to confirm T172 phosphorylation as a predictive biomarker for CDK4/6 inhibitor sensitivity .